Evolution of the Average Target: Xylem Inc.

Evolution of the Target Price: Xylem Inc.

Changes in Analyst Recommendations: Xylem Inc.

4c8b694.BtlkFmUN-M3-v4r9o1_ZH9i3GXEyqRfMjYMtqX4gQSQ.Y-4-UFRIzr2oz8i75DK6UonwRgJ3z0aO9eEezQ1qGXd0kjVGHTSMhKvXsg~62c949d68253035c9bf705f20cc5f756
07-30 UBS Adjusts Price Target on Xylem to $135 From $129, Maintains Neutral Rating MT
07-29 Xylem's Guidance Boost Driven by Buybacks, Bolt-On Acquisition, RBC Says MT
07-29 RBC Raises Price Target on Xylem to $164 From $159, Keeps Outperform Rating MT
07-29 Deutsche Bank Adjusts Xylem Price Target to $151 From $149, Maintains Buy Rating MT
07-29 JPMorgan Adjusts Price Target on Xylem to $137 From $130, Maintains Neutral Rating MT
07-29 Barclays Adjusts Price Target on Xylem to $159 From $154, Maintains Overweight Rating MT
07-29 Baird Adjusts Price Target on Xylem to $165 From $163, Maintains Outperform Rating MT
07-29 Stifel Adjusts Price Target on Xylem to $160 From $157, Maintains Buy Rating MT
07-29 Goldman Sachs Adjusts Price Target on Xylem to $160 From $153, Maintains Buy Rating MT
07-29 Citigroup Adjusts Price Target on Xylem to $172 From $168, Maintains Buy Rating MT
07-29 Mizuho Adjusts Price Target on Xylem to $130 From $124, Maintains Neutral Rating MT
07-21 JPMorgan Downgrades Xylem to Neutral From Overweight, Cuts Price Target to $130 From $140 MT
07-20 Jefferies Adjusts Price Target on Xylem to $145 From $140, Maintains Buy Rating MT
07-20 Stifel Adjusts Price Target on Xylem to $157 From $159, Maintains Buy Rating MT
07-16 RBC Capital Adjusts Price Target on Xylem to $159 From $157, Maintains Outperform Rating MT
07-14 Xylem Likely Approaching Growth Inflection, Oppenheimer Says MT
07-06 UBS Adjusts Xylem Price Target to $129 From $133 MT
06-25 Xylem Shares Rise After Jefferies Upgrade MT
06-25 Jefferies Upgrades Xylem to Buy From Hold, Adjusts Price Target to $140 From $130 MT
05-19 Argus Adjusts Price Target on Xylem to $125 From $150, Maintains Buy Rating MT
04-29 Mizuho Adjusts Price Target on Xylem to $124 From $138, Maintains Neutral Rating MT
04-29 Oppenheimer Adjusts Price Target on Xylem to $158 From $160, Maintains Outperform Rating MT
04-29 UBS Adjusts Price Target on Xylem to $133 From $132, Maintains Neutral Rating MT
04-29 Deutsche Bank Adjusts Xylem Price Target to $155 From $153, Maintains Buy Rating MT
04-29 Baird Adjusts Price Target on Xylem to $163 From $161, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+6.47%
+4.56%
+12.64%
+9.03%
+15.36%
+20.98%
+4.07%
+2.58%
- +73.81%
Average +16.61%
Weighted average by Cap. +12.63%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
116.97USD
Average target price
153.41USD
Spread / Average Target
+31.15%
High Price Target
183.00USD
Spread / Highest target
+56.45%
Low Price Target
129.00USD
Spread / Lowest Target
+10.28%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
RBC Capital Markets
Deutsche Bank Securities
JPMorgan Chase
Barclays
Baird
Stifel Nicolaus
Goldman Sachs
Citigroup
Mizuho Securities
Jefferies & Co.
Argus
Oppenheimer
BNP Paribas
William Blair & Co.
BNP Paribas Exane
Rothschild & Co Redburn
TD Cowen
Redburn Atlantic
Wolfe Research
Melius Research
Seaport Global Securities
Cowen
Morgan Stanley
Raymond James
Atlantic Equities
Credit Suisse
Berenberg Bank
Loop Capital
Rosenblatt Securities
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
116.97USD
Average target price
153.41USD
Spread / Average Target
+31.15%

Quarterly revenue - Rate of surprise